<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02247492</url>
  </required_header>
  <id_info>
    <org_study_id>G1406</org_study_id>
    <nct_id>NCT02247492</nct_id>
  </id_info>
  <brief_title>BIOFLOW-III VIP Russia Registry Orsiro Stent System</brief_title>
  <official_title>BIOTRONIK - SaFety and Performance Registry for an All-comers Patient Population With the Limus Eluting Orsiro Stent System Within Daily Clinical Practice - III and Vulnerable Inflammation Parameter Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biotronik Russia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biotronik Russia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with&#xD;
      Drug Eluting Stents (DES). Along with it, an explanatory (hypothesis-finding) problem will be&#xD;
      investigated, whether the patient's body inflammation status correlates with the clinical&#xD;
      outcome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For the majority of Coronary Artery Disease (CAD) treatment with Percutaneous Transluminal&#xD;
      Coronary Angioplasty (PTCA) provides high initial procedure success. However, the medium to&#xD;
      long-term complications range from rather immediate elastic coil or vessel contraction to&#xD;
      longer processes like smooth muscle cell proliferation and excessive production of extra&#xD;
      cellular matrix, thrombus formation and atherosclerotic changes like restenosis or&#xD;
      angiographic re-narrowing. The reported incidence of restenosis after PTCA ranges from 30 to&#xD;
      50%. Such rates of recurrence have serious economic consequences. Bare Metal Stents (BMS),&#xD;
      designed to address the limitations of PTCA, reduced the angiographic and clinical restenosis&#xD;
      rates in De Novo lesions compared to PTCA alone and decreased the need for CABG. BMS&#xD;
      substantially reduced the incidence of abrupt artery closure, but restenosis still occurred&#xD;
      in about 20 to 40% of cases, necessitating repeat procedures.&#xD;
&#xD;
      The invention of Drug Eluting Stents (DES) significantly improved on the principle of BMS by&#xD;
      adding an antiproliferative drug (directly immobilized on the stent surface or released from&#xD;
      a polymer matrix), which inhibits neointimal hyperplasia. The introduction of DES greatly&#xD;
      reduced the incidence of restenosis and resulted in better safety profile as compared to BMS&#xD;
      with systemic drug administration. These advantages and a lower cost compared to surgical&#xD;
      interventions has made DES an attractive option to treat coronary artery disease.&#xD;
&#xD;
      Therefore this observational registry has been designed for the clinical evaluation of the&#xD;
      ORSIRO LESS requiring coronary revascularization with DES. It is designed to investigate and&#xD;
      collect clinical evidence for the clinical performance and safety of the Orsiro Drug Eluting&#xD;
      Stent System in an all-comers patient population in daily clinical practice.&#xD;
&#xD;
      Along with it, an explanatory (hypothesis-finding) problem will be investigated, whether the&#xD;
      patient's body inflammation status correlates with the clinical outcome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">April 14, 2017</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>36 Months</target_duration>
  <primary_outcome>
    <measure>Target Lesion Failure (TLF)</measure>
    <time_frame>12 months</time_frame>
    <description>Composite of cardiac death, target vessel Q-wave or non Q-wave Myocardial Infarction (MI), Coronary Artery Bypass Graft (CABG) and clinically driven Target Lesion Revascularization (TLR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Failure (TLF)</measure>
    <time_frame>6 and 36 months</time_frame>
    <description>Composite of cardiac death, target vessel Q-wave or non-Q wave Myocardial Infarction (MI), Emergent Coronary Artery Bypass Graft (CABG), clinically driven Target Lesion Revascularization (TLR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Revascularization (TVR)</measure>
    <time_frame>6 and 36 months</time_frame>
    <description>Any repeat revascularization of the target vessel.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR)</measure>
    <time_frame>6 and 36 months</time_frame>
    <description>Defined as any repeat revascularization of the target lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis</measure>
    <time_frame>6, 12 and 36 months</time_frame>
    <description>Definite, Probable and Possible Stent Thrombosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Device Success</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 1 day</time_frame>
    <description>Successful delivery and deployment of the investigational stent (s) at the intended target lesion and successful withdrawal of the stent delivery system with attainment of a final residual stenosis of less than 50% by visual estimation and without use of device outside the assigned treatment strategy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical procedural success</measure>
    <time_frame>up to seven days</time_frame>
    <description>Successful delivery and deployment of the investigational stent (s) at the intended target lesion and successful withdrawal of the stent delivery system with attainment of a final residual stenosis of less than 50% by visual estimation and without using any adjunctive device without the occurrence of ischemia-driven major adverse cardiac event during the hospital stay to a maximum of the first seven days post index procedure.&#xD;
In case of multiple lesions treatment, all treated lesions must meet the clinical procedural success.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vulnerable Inflammation Parameter (VIP)</measure>
    <time_frame>up to 36 months</time_frame>
    <description>VIP registered ad Endotoxin concentration in patients blood serum</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Coronary Artery Diseases</condition>
  <arm_group>
    <arm_group_label>Orsiro</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        All subjects requiring coronary revascularization with Drug Eluting Stents (DES)&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Symptomatic coronary artery disease&#xD;
&#xD;
          -  Subject signed informed consent for data release&#xD;
&#xD;
          -  Subject is geographically stable and willing to participate at all follow up&#xD;
             assessments&#xD;
&#xD;
          -  Subject is â‰¥ 18 years of age&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject did not sign informed consent&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Known intolerance to aspirin, clopidogrel, Ticlopidine, heparin or any other&#xD;
             anticoagulant/antiplatelet therapy required for PCI, stainless steel, Sirolimus or&#xD;
             contrast media&#xD;
&#xD;
          -  Planned surgery within 6 months after PCI unless dual antiplatelet therapy will be&#xD;
             maintained&#xD;
&#xD;
          -  Currently participating in another study and primary endpoint not reached yet&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Evgeny Kretov, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novosibirsk Research Institute for Circulation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ildar Khassanov, Dr.</last_name>
    <phone>+49 9131 852 56 34</phone>
    <email>ildar.khassanov@biotronik.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ural Institute of Cardiology</name>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Freidlin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research Institute for Complex Problems of Cardiovascular Diseases</name>
      <address>
        <city>Kemerovo</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gonyukov, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital</name>
      <address>
        <city>Nizhniy Novgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonina Bogush, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Novosibirsk Scientific Research Institute of Circulation Pathology</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Evgeniy Kretov</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>City Emergency Clinical Hospital of Rostov-on-Don</name>
      <address>
        <city>Rostov-on-Don</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Ponomarev, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>North-West Federal Medical Research Center named after V.A. Almazov</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexey Yakovlev</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Cardiology, Tomsk Medical Research</name>
      <address>
        <city>Tomsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergey Popov</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>September 17, 2014</study_first_submitted>
  <study_first_submitted_qc>September 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2014</study_first_posted>
  <last_update_submitted>July 19, 2018</last_update_submitted>
  <last_update_submitted_qc>July 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>International</keyword>
  <keyword>Multicenter</keyword>
  <keyword>Observational registry</keyword>
  <keyword>Orsiro Drug Eluting Stent (DES)</keyword>
  <keyword>Stenting</keyword>
  <keyword>Treatment of coronary artery disease</keyword>
  <keyword>Coronary revascularization</keyword>
  <keyword>Percutaneous Coronary Intervention (PCI)</keyword>
  <keyword>STEMI</keyword>
  <keyword>NSTEMI</keyword>
  <keyword>Ischemia</keyword>
  <keyword>Angina</keyword>
  <keyword>Acute Myocardial Infarction (AMI)</keyword>
  <keyword>Small Vessels</keyword>
  <keyword>Chronic Total Occlusion (CTO</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

